AcelRx Pharmaceuticals Inc. (ACRX)

2.91
0.03 1.00
NASDAQ : Health Technology
Prev Close 2.94
Open 2.99
Day Low/High 2.89 / 3.04
52 Wk Low/High 1.65 / 5.05
Volume 614.51K
Avg Volume 3.83M
Exchange NASDAQ
Shares Outstanding 76.39M
Market Cap 240.64M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AcelRx Pharmaceuticals To Host Analyst And Investor Day On December 11

AcelRx Pharmaceuticals To Host Analyst And Investor Day On December 11

Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals

Stocks Under $10 Weekly Summary

Given the market pressures of last week, there was little room to hide as the gut punches continued to hit small-cap and technology stocks.

Stocks Under $10 Weekly Summary

We added to several positions on weakness last week.

Stocks Under $10 Weekly Summary

Despite swimming against the recent tide with small-cap stocks, we have several positions that are more than holding their own.

Portfolio Name's Stock Offering Is Dilutive

We are not adding to our AcelRx position on this weakness, despite believing in the underlying story, until we have more information.

AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

AcelRx Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

REDWOOD CITY, Calif., Nov.

AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

REDWOOD CITY, Calif., Nov.

Election Impact on the Portfolio

While health care holdings may suffer, cannabis-related holdings should get a boost.

Stocks Under $10 Weekly Summary

We saw a number of our positions rebound along with the market last week.

AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Corporate Update

AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Corporate Update

- FDA approved DSUVIA™ for use in adults in a certified medically supervised healthcare setting for the management of acute pain

AcelRx Announces FDA Approval Of DSUVIA™

AcelRx Announces FDA Approval Of DSUVIA™

- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings

Stocks Under $10 Weekly Summary

We re-initiated a position during a volatile week in the market.

Sailing Stormy Seas, Plus Updates on 3 Positions

Here’s when we would consider adding to Aurora Cannabis.

First Week Of June 2019 Options Trading For AcelRx Pharmaceuticals (ACRX)

First Week Of June 2019 Options Trading For AcelRx Pharmaceuticals (ACRX)

Investors in AcelRx Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Stocks Under $10 Weekly Summary

Amid volatile market activity, we added to four positions last week.

Adding to the Portfolio’s ‘Wild Child’

We are buying more shares of AcelRx Pharmaceuticals following an FDA advisory committee’s approval of its NDA candidate.

Stocks Under $10 Weekly Summary

The majority of our positions outperformed our benchmark during a challenging week for the stock market.

Insiders Seeing Green With ACRX At New 52-Week High

Insiders Seeing Green With ACRX At New 52-Week High

In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.03/share. That's a 224.52% rise, or $3.48 per share from the 52-week low of $1.55 set back on 10/19/2017.

It’s a Key Day for This Specialty Pharma Position

FDA review of AcelRx Pharma's DSUVIA should produce a significant reaction in the shares.

Stocks Under $10 Weekly Summary

We added to four positions during a rough week for small-cap names.

Stocks Under $10 Weekly Summary

We initiated a new position and added to a newer name during a mixed week for the portfolio.

Analyzing a Position’s Ups and Downs

There are several reasons to believe in AcelRx Pharmaceuticals’ recent rise.

TheStreet Quant Rating: D- (Sell)